Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan.

• Tác giả: Ming-Jong Bair, Chun-Chao Chang, Te-Sheng Chang, Chi-Yi Chen, Chun-Ting Chen, Guei-Ying Chen, Chien-Yu Cheng, Pin-Nan Cheng, Lee-Won Chong, Wang-Long Chuang, Chia-Yen Dai, Tsai-Yuan Hsieh, Jui-Ting Hu, Chia-Sheng Huang, Chien-Wei Huang, Chung-Feng Huang, Jee-Fu Huang, Yi-Hsiang Huang, Chao-Hung Hung, Chien-Neng Kao, Jia-Horng Kao, Hsing-Tao Kuo, Mei-Hsuan Lee, Pei-Lun Lee, Tzong-Hsi Lee, Chih-Lang Lin, Chih-Lin Lin, Han-Chieh Lin, Chun-Jen Liu, Ching-Chu Lo, Lein-Ray Mo, Cheng-Yuan Peng, Wei-Wen Su, Chi-Ming Tai, Pei-Chien Tsai, Kuo-Chih Tseng, Chia-Chi Wang, Shu-Chi Wang, Szu-Jen Wang, Wen-Chih Wu, Chi-Chieh Yang, Sheng-Shun Yang, Ming-Lun Yeh, Ming-Lung Yu
• Ngôn ngữ: eng
• Ký hiệu phân loại: 297.1248 Sources of Islam
• Thông tin xuất bản: China (Republic : 1949- ) : The Kaohsiung journal of medical sciences , 2025
• Bộ sưu tập: NCBI
• ID: 60850

Tóm tắt

 An 8-week regimen of glecaprevir/pibrentasvir is recommended for treatment-naïve patients with chronic hepatitis C (CHC). In alignment with the Taiwanese government's objective to eliminate hepatitis C by 2025, this study aimed to provide real-world evidence on the use of this regimen in treatment-naïve patients with chronic kidney disease (CKD) by using data from the Taiwan Association for the Study of the Liver HCV Registry (TACR). CKD was defined by an estimated glomerular filtration rate (eGFR) of <
 60 mL/min/1.73 m